Refine
Document Type
- Article (1)
- Part of Periodical (1)
Language
- English (2)
Has Fulltext
- yes (2)
Is part of the Bibliography
- no (2)
Keywords
- Atka Bay (1)
- Rhopalonematidae (1)
- Trachymedusae (1)
- hydromedusa (1)
- sympagic (1)
Institute
- Medizin (1)
A new genus and species of sympagic trachymedusa, Glaciambulata neumayeri gen. et sp. nov., are described based on material from Antarctica. Its generic features are compared to those of its relatives, Ptychogastria Allman, 1878 and Tesserogastria Beyer, 1959, and a review of the family Ptychogastriidae Mayer, 1910, based on literature data, is provided. From this, it results that the poorlyknown Pectis antarctica Haeckel, 1879, formerly assigned to Ptychogastria by a number of authors, displays all characters of the contemporary rhopalonematid genus Voragonema Naumov, 1971. It is additionally demonstrated that V. laciniata Bouillon et al., 2001 is coterminous with P. antarctica, a finding that clarifies, 137 years later, the morphology and the taxonomic status of Haeckel’s medusa. In accordance with the Principle of Priority, Pectis is recognized as the valid name of the genus, and Voragonema is assigned to its synonymy. Similarly so, the specific name introduced by Haeckel has priority over laciniata.
Background and Aims: The prevalence of hepatitis C virus (HCV) antibodies in Germany has been estimated to be in the range of 0.4–0.63%. Screening for HCV is recommended in patients with elevated ALT levels or significant risk factors for HCV transmission only. However, 15–30% of patients report no risk factors and ALT levels can be normal in up to 20–30% of patients with chronic HCV infection. The aim of this study was to assess the HCV seroprevalence in patients visiting two tertiary care emergency departments in Berlin and Frankfurt, respectively.
Methods: Between May 2008 and March 2010, a total of 28,809 consecutive patients were screened for the presence of anti-HCV antibodies. Anti-HCV positive sera were subsequently tested for HCV-RNA.
Results: The overall HCV seroprevalence was 2.6% (95% CI: 2.4–2.8; 2.4% in Berlin and 3.5% in Frankfurt). HCV-RNA was detectable in 68% of anti-HCV positive cases. Thus, the prevalence of chronic HCV infection in the overall study population was 1.6% (95% CI 1.5–1.8). The most commonly reported risk factor was former/current injection drug use (IDU; 31.2%) and those with IDU as the main risk factor were significantly younger than patients without IDU (p<0.001) and the male-to-female ratio was 72% (121 vs. 46 patients; p<0.001). Finally, 18.8% of contacted HCV-RNA positive patients had not been diagnosed previously.
Conclusions: The HCV seroprevalence was more than four times higher compared to current estimates and almost one fifth of contacted HCV-RNA positive patients had not been diagnosed previously.